Frontlight ResearchEarly access
CompletedPhase 2
Cytomegalovirus Prophylaxis with Letermovir in Heart Transplant Recipients: A Non-randomized Cohort Pilot Study
Key facts
- Who runs it
- University Medical Center Ljubljana
- Where
- Slovenia1 site in 1 countryChoose a country to see its sites
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 90 people enrolled
- Started
- 17 Sept 2024
- Ended
- 1 May 2026
- Type of study
- Interventional
- Record updated
- 17 September 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- •heart transplant recipient (new)
- •moderate (D+/R+ and D-/R+) or high (D+/R-) risk CMV serostatus
- •signed informed consent for participation in the study
- age ≥ 18 years; •not enrolled in competing clinical trials
Who cannot take part
- •short-term mechanical circulatory support prior HTX
- •concomitant administration with pimozide
- •concomitant administration with ergot alkaloids
- •concomitant administration with St. John’s wort (Hypericum perforatum)
- •multi-organ transplantation
- •concomitant administration of cyclosporine
- •concomitant use of dabigatran, atorvastatin, simvastatin, rosuvastatin or pitavastatin is contraindicated
- •Has previously participated in this study or any other study involving letermovir
- •Has previously participated or is currently participating in any study involving administration of a CMV vaccine or another CMV investigational agent, or is planning to participate in a study of a CMV vaccine or another CMV investigational agent during the course of this study
- •need for intensified immunosuppression protocol (>20% cytolytic alloantibodies prior transplant or perioperative (within 7 days after HTX) allograft rejection > 1R)
- •known hypersensitivity to letermovir
- •known hypersensitivity to valgancyclovir
- •known hematological disorders (apart from anemia)
- •advanced kindey disease (CrCL < 10 ml/min) at enrollment
- •advanced liver disease (Child Pugh Class C)
- •combined moderate kidney (CrCL < 50 ml/min) and liver (Child Pugh Class B) insufficiency at screening
- •combined hepatic and renal impairment
- •HIV infection
- •Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or put the participant at undue risk, as judged by the investigator, such that it is not in the best interest of the participant to participate in this study
- •ongoing CMV infection/disease
- •heart re-transplantation
- •known hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption
- •history of malignancy (< 5 years; except adequately treated basal or squamous cell skin cancer or in situ cervical cancer) or under evaluation for active or suspected malignancy
- •D-/R- CMV serostatus
- •immunoinduction with ATG
- •pregnancy
- •active participation in another interventional clinical trial
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective of the study is to investigate the efficacy of letermovir-based CMV prophylaxis in patients after heart transplantation.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Record updated
- 17 September 2024